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ABSTRACT
Background Among high- income countries, South Korea 
has a considerable tuberculosis (TB) burden; North Korea 
has one of the highest TB burdens in the world. Predicting 
the impact of control strategies on the TB burden can help 
to efficiently implement TB control programmes.
Methods We designed a deterministic compartmental 
model of TB in Korea. After calibration with notification of 
incidence data from South Korea, the TB burden for 2040 
was predicted according to four different intervention 
strategies: latent TB infection (LTBI) treatment, rapid 
diagnosis, active case- finding and improvement of the 
treatment success rate. North Korea’s burden in 2040 was 
similarly estimated by adjusting the model parameters.
Results In South Korea, the number of patients with drug- 
susceptible TB (DS- TB) and multidrug- resistant TB (MDR- 
TB) were predicted to be 27 581 and 625, respectively, in 
2025. Active case- finding would lower DS- TB by 6.2% and 
MDR- TB by 26.7%, respectively, in 2040. The improvement 
in the success rate of DS- TB treatment would reduce the 
MDR- TB burden by 34.5%. In North Korea, the number 
of patients with DS- TB and MDR- TB are, respectively, 
predicted to be 77 629 and 5409 in 2025. Active case- 
finding would reduce DS- TB by 22.2% and MDR- TB by 
69.7%. LTBI treatment would reduce DS- TB by 20.6% and 
MDR- TB by 38.6%.
Conclusion The impact of control strategies on the TB 
burden in South and North Korea was investigated using a 
mathematical model. The combined intervention strategies 
would reduce the burden and active case- finding is 
expected to result in considerable reduction in both South 
and North Korea.
INTRODUCTION
Tuberculosis (TB), a communicable disease 
that is a major cause of ill health, is one of 
the top 10 causes of death worldwide and the 
leading cause of death from a single infectious 
agent.1 Despite efforts to eliminate TB based 
on the WHO’s END TB strategy2 and a polit-
ical declaration at a UN high- level meeting,3 
an estimated 10 million people suffered 
from TB in 2018. Moreover, drug- resistant 
TB continues to be a threat to public health. 
Only 39% of the estimated 484 000 rifampin- 
resistant (RR)/multidrug- resistant (MDR)- TB 
cases were reported, and worldwide the treat-
ment success rate for RR/MDR- TB was 56% in 
the 2016 cohort.4 It is clear that to achieve the 
objectives of the END TB strategy, the expan-
sion of TB control programmes, including 
the preventive treatment of persons at high 
Key questions
What is already known?
 ► Tuberculosis(TB) is a significant challenge in the 
Korean peninsula. North Korea is one of the 30 
countries with the highest TB and drug resistant TB 
burdens and TB incidence in South Korea is consid-
erable among high income countries.
 ► There are relatively few studies on the modelling of 
drug resistant TB incorporating to the drug suscep-
tible TB.
What are the new findings?
 ► Using reported national TB data from South and 
North Korea, local epidemiologic parameters, we de-
veloped a dynamic model for drug susceptible (DS) 
and multidrug- resistant (MDR)TB in South and North 
Korea. DS and MDR- TB continuously decreased and 
active case finding (ACF) and the improvement of 
DS- TB treatment were effective in reducing TB bur-
dens in South Korea. In North Korea, MDR- TB bur-
dens increased even several interventions. ACF and 
improvement of diagnostics and DS- TB treatment 
were effective in reducing MDR- TB in North Korea.
What do the new findings imply?
 ► The DS- TB and MDR- TB incorporating model we de-
veloped can help estimate the impact of TB control 
strategies comprehensively. In resource limited set-
tings such as North Korea, to overcome the burden 
of drug resistant TB, a sustainable and comprehen-
sive TB control strategy that focuses on both DS- TB 
and MDR- TB is necessary.
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risk, early diagnosis of TB and improvement of treatment 
outcomes is essential.
Because of the slow disease dynamics of TB, mathe-
matical and computational models are useful in fore-
casting the long- term evolution of the TB epidemic and 
for planning and resource allocation in public health. 
Therefore, several mathematical simulation models have 
been combined to predict the effect of public health 
interventions on TB control programmes.5–7 However, 
there are few models for the prediction of drug- resistant 
TB epidemiology that incorporate drug- susceptible (DS)- 
TB. Drug- resistant TB is a significant challenge in the 
Korean peninsula. North Korea is one of the 30 coun-
tries with the highest TB and RR/MDR- TB burdens and 
the reported and estimated number of TB has increased 
(345/100 000 in 2010 to 513/100 000 in 2018).4 Among 
high- income countries, South Korea also has a consider-
able TB burden. The reported incidence was 96.4/100 
000 in 2010 and 65.9/100 000 in 2018.8 Even though 
South Korea has achieved considerable reduction of TB 
in the past, TB incidence in South Korea is seven times 
higher than the average incidence for member countries 
of the Organization for Economic Co- Operation and 
Development.1
Recently, molecular test for raid diagnosis of TB and 
rifampin resistance are rolling out globally and several 
studies showed promising impact of this intervention 
for TB and RR/MDR- TB control.9 10 Also, newly intro-
ducing new drugs for RR/MDR- TB treatment such as 
bedaquiline and delamanid suggest possible all oral regi-
mens and improved outcome of RR/MDR- TB.11 12
The purpose of this study was to develop a mathemat-
ical model that accounts for recent trends in DS- TB and 
RR/MDR- TB incidence and to predict TB burden based 
on the proposed optimal TB control intervention strategy 
in South and North Korea.
We developed a deterministic compartmental model 
by incorporating the recent understanding of TB epide-
miology, which aims to compare various intervention 
scenarios in response to TB. The model allows a systemic 
approach to planning control strategies considering 
multiple aspects of TB in South and North Korea.
METHODS
Study design
We constructed a deterministic compartmental model 
for TB. The basic structure of the TB model follows the 
Susceptible- Exposed- Infectious- Treated model but was 
modified by considering additional factors to reflect the 
characteristics of TB. We divided the latent TB infection 
compartment into fast progressors, E (approximately 5% 
of healthy adults will develop the active disease within 
2 years), and slow progressors, L (individuals who do not 
have rapid progression). In addition, we differentiated 
between DS- TB and RR/MDR- TB populations to predict 
the long- term incidence of TB. Independent experi-
ments were performed for South and North Korea. Our 
main interest is predicting the future incidence of TB 
and the number of TB deaths in South and North Korea 
by 2040. We also performed a sensitivity analysis to assess 
the reliability of the predictions.
Patient and public involvement
Patients were not involved in this study.
Mathematical model
The model population was compartmentalised and clas-
sified by the status of the disease: susceptible (S), latent 
Figure 1 Diagram of TB transmission model. TB, tuberculosis.
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infection (E and L), infectious (I), treated (T), untreated 
(UT) and relapsed (R). The population was also divided 
according to susceptibility to TB drugs (DS or RR/MDR). 
Figure 1 shows a flow diagram of a dynamic TB transmis-
sion model.
Briefly, the key model assumption includes all TB- in-
fected individuals harbouring a single TB strain with a 
specified drug resistance pattern at any particular time. 
RR/MDR- TB is acquired by being infected with resistant 
strains, by de novo mutations during non- curative therapy, 
or relapse. Individuals who progress to the treatment (T) 
stage can be placed in three categories. The basic case of 
transition from the infectious state to the treated state is 
 TDS(a2, b1) . When patients with RR/MDR- TB are started 
on the DS- TB treatment  (b1) , they can move to the  TMDR   
state after drug susceptibility test results are obtained. In 
the second category, diagnosed patients progress to the 
 TMDR   state if RR/MDR- TB is immediately diagnosed using 









Patients with misdiagnosed DS- TB can move back to the 
 TDS   state with drug susceptibility test results. Progression 
to the untreated state (UT) occurs when the diagnosis 
is further delayed in the medical institutions by the AFB 
smear testing negative or TB- PCR ( a3, b3 ). Then, they 
progress to the  TDS   state at the rate of  γ  after additional 
examination.
People in the slow progress latent (L) state are 
assumed to have partial immunity to TB, which leads to 
a 35% reduction in the force of infection compared with 
people in the susceptible (S) state.6 Coinfection with HIV 
was not considered because such cases constitute a small 
proportion of all TB cases in South and North Korea.
Data and parameters
The parameter values were determined using published 
literature reviews, estimated, derived or assumed based 
on the best available local epidemiological data and 
mathematical formulas. Table 1 provides a summary of 
the descriptions and values used in the simulations.
In assessing the data of reported TB cases in South 
Korea, the number of reported cases is observed to 
have decreased rapidly since 2011. We hypothesised 
that this decline has been accelerated due to increased 
contact investigation and preventive treatment interven-
tions compared with the previous period. Therefore, 
the proportion of rapid progression to active TB from 
the high- risk latent state has been deemed to decrease 
linearly between 2011 and 2019. Then, the transmission 
rate β and progression rate from slow progress latent to 
infectious τ were estimated by fitting the model to the 
incidence data of TB in South Korea from 2011 to 2019 
(figure 2). Maximum likelihood estimation technique 
was employed assuming Poisson distribution for the inci-
dence data in model calibration.
For North Korea, the parameter values were deter-
mined similarly to those of South Korea, where global 
and regional WHO reports were used. The parameter 
values were adjusted using published literature reviews, 
values for South Korea and estimation based on the best 
available local epidemiological data.
TB intervention strategy
South Korea
The proportion of high- risk, latent to active TB decreased 
linearly from 5.1% to 4.4% from 2011 to 2019. Reflecting 
this trend, an additional level of preventive therapy was 
imposed until the proportion reached 3.6% in 2025 for 
the baseline case (table 2).
Scenario 1—Preventive treatment control: Since 
preventive therapy affects the proportion of the high- risk 
latent to active TB group, we applied a gradual reduction 
of the flow from E to I to implement this intervention.
Scenario 2—Diagnostic improvement: In this scenario, 
the proportion of active TB would be improved with accu-
rate diagnosis and proper treatment. This was adjusted 
by changing the proportion of the flow to the  TMDR, TDS   
and  UT  compartments. The baseline assumption was that 
60% of DS- TB and 51% of MDR- TB moved to the  TDS  
state, which increased up to 80% in this scenario.
Scenario 3—Active case- finding strategy: The infectious 
period of active TB would be reduced by scaling up the 
discovery of active cases. Therefore, the third interven-
tion was imposed by reducing the value of the diagnostic 
delay parameter for the infectious individuals to receive 
treatment. The baseline was assumed to be 180 days, and 
the intervention scenario was tested by reducing patient 
delay to 150 days.
Figure 2 Model calibration results for South Korea. DS, 
drug- susceptible; MDR, multidrug- resistant; TB, tuberculosis.
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Scenario 4—Scaling up the treatment success rate for 
active TB: This intervention was experimented on by 
changing the treatment success rate values of DS- TB and 
RR/MDR- TB. In the baseline case, the treatment success 
rates for DS- TB and RR/MDR- TB were 92.5% and 87.5%, 
respectively. In this scenario, the treatment success rate 
was increased to 97.5% for each DS- TB and RR/MDR- TB.
All interventions, except changes to the treatment 
success proportion, were applied simultaneously to both 
DS- TB and RR/MDR- TB.
North Korea
For North Korea, all four scenarios in the South Korean 
intervention were similarly applied, but the model 
parameters for the interventions were adjusted to the 
North Korean situation.
Sensitivity analysis
Sensitivity analyses were performed to examine the 
robustness of the model simulation results regarding 
the uncertainty of the parameter values. We perturbed 
each parameter by 5% of their values and compared the 
number of DS- TB and RR/MDR- TB cases predicted in 
2040.
RESULTS
TB cases prevented by interventions in South Korea
In the baseline case, the proportion of progression to 
active TB from the high risk latent group decreased line-
arly from 5.1% to 4.4% from 2011 to 2019, and an addi-
tional level of preventive therapy was imposed until the 
proportion reached 3.6% by 2025 (table 2). Our model 
projected that incident cases of DS- TB and RR/MDR- TB, 
respectively, would drop to 27 581 and 625 by 2025. By 
maintaining a consistent setting after 2025, the number 
of new cases of DS- TB and RR/MDR- TB decreases slightly. 
The impact of four different TB control strategies on the 
incident cases was tested based on this situation.
To investigate the effects of preventive treatment inter-
vention, the model was simulated assuming a consistent 
level of preventive therapy control from 2020 for the 
proportion to reach 3.9% in 2025 (table 2, figure 3). 
Without additional preventive therapy control from 
2020 to 2025, the reported TB cases increase by 356 in 
2040 and 6491 cumulatively from 2020 to 2040 (table 3, 
figure 3).
Regarding the diagnosis improvement intervention, 
60% of patients with DS- TB were treated immediately 
without hospital delay and, in the baseline case, the 
remainder had an average hospital delay of 22 days.13 Only 
9% of patients with RR/MDR- TB started RR/MDR- TB 
treatment immediately, and 51% initially received DS- TB 
treatment and started RR/MDR- TB treatment after the 
drug susceptibility test. In the diagnostic improvement 
control scenario, the proportion of patients without 
hospital delay was set at 80% for both DS- TB and RR/
MDR- TB (table 4, figure 4).
As a result, it was expected to reduce, respectively, 
the 3287 and 2380 additional DS- TB and RR/MDR- TB 
cases between 2020 and 2040. The impact of diagnostic 
improvement was more prominent in RR/MDR- TB cases.
The effect of the active case- finding strategy was esti-
mated by reducing the time taken until the patient is 
treated. The baseline value was 180 days, which was short-
ened to 150 days in the intervention scenario (table 5, 
figure 5).
Figure 3 Number of reported TB cases with different 
preventive therapies implemented during 2020–2025 in 
South Korea. DS, drug- susceptible; MDR, multidrug- 
resistant; TB, tuberculosis.
Table 2 Cumulative number of reported TB cases, annual new infection and death predictions under the baseline scenario in 
South Korea
2020 2025 2030 2035 2040
Cumulative DS report 29 767 171 926 305 421 432 715 554 258
Cumulative MDR report 655 3835 6897 9885 12 810
Yearly new infection 96 825 91 372 88 220 85 548 82 925
Death by TB 4582 4248 4023 3842 3673
DS, drug- susceptible ; MDR, multidrug- resistant; TB, tuberculosis.
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By reducing the delay to 150 days, the annual new 
infection rate significantly decreases to 64 953 in 2040, 
compared with 82 925 in the baseline scenario. A cumula-
tive reduction, respectively, of 20 962 and 2584 reported 
DS- TB and RR/MDR- TB cases between 2020 and 2040 
was expected.
Finally, the treatment success rate was improved by 
increasing the success rate for DS- TB from 92.5% to 
97.5% and the RR/MDR- TB success rate from 87.5% to 
97.5% in a separate simulation (tables 6 and 7, figures 6 
and 7). The improvement in the DS- TB treatment success 
rate, respectively, reduced the 25 045 and 3876 cumula-
tive reported cases of DS- TB and RR/MDR- TB between 
2020 and 2040. Conversely, the control of RR/MDR- TB 
only decreased DS- TB cases by 4 and RR/MDR- TB 
cases by 1118 cumulatively during 2020 and 2040. It 
was observed that amelioration of the DS- TB treatment 
success rate had a greater impact on both the DS- TB and 
RR/MDR- TB cases.
Sensitivity analysis in South Korea
We measured the sensitivity of the TB burden in 2040 
regarding the model parameters by perturbing 5% of the 
value of each parameter (figure 8). While the reported 
cases of DS- TB were most sensitive to the progression 
rate from the low- risk latent to infectious, MDR- TB was 
most sensitive to the proportion of DS treatment success. 
Diagnostic delay and transmission rate played key roles 
in both DS and MDR infection dynamics. The proportion 
of successful DS treatments, death rate adjusted for DS 
infection and the proportion of rapid progression from 
latent to DS- infectious were also significant in the results 
of the DS- TB cases. The MDR- TB cases were highly sensi-
tive to the progression rate from the low- risk latent to 
infectious and the proportion of successful MDR treat-
ments.
Prevented TB cases by interventions and sensitivity analysis 
in North Korea
The number of reported incident cases for DS- TB 
and estimated incident cases for RR/MDR- TB slightly 
increased from 2012 to 2015 and decreased from 2015 
to 2019 in North Korea. All parameters were assumed to 
be constant from 2012 to 2019. Assuming all parameters 
remain constant, new cases of DS- TB decreased slightly, 
Table 3 Cumulative number of reported TB cases, annual new infection and death predictions with consistent preventive 
therapy from 2020 to 2025 in South Korea
2020 2025 2030 2035 2040
Cumulative DS report 29 818 173 063 308 331 437 421 560 749
Cumulative MDR report 655 3842 6924 9937 12 888
Yearly new infection 96 986 92 391 89 400 86 735 84 112
Death by TB 4587 4290 4076 3896 3727
DS, drug- susceptible ; MDR, multidrug- resistant; TB, tuberculosis.
Table 4 Cumulative number of reported TB cases, annual new infection and death predictions with diagnostic improvements 
in South Korea
2020 2025 2030 2035 2040
Cumulative DS report 29 758 171 354 304 053 430 437 550 971
Cumulative MDR report 622 3288 5756 8131 10 430
Yearly new infection 93 907 87 752 84 616 81 962 79 355
Death by TB 4563 4161 3931 3748 3577
DS, drug- susceptible ; MDR, multidrug- resistant; TB, tuberculosis.
Figure 4 Number of reported TB cases with diagnostic 
improvement in South Korea. DS, drug- susceptible; MDR, 
multidrug- resistant; TB, tuberculosis.
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but cases of RR/MDR- TB were expected to increase grad-
ually (online supplemental table S1).
The impact was assessed of four different TB control 
strategies on the incident cases, taking this situation as 
a baseline. The qualitative results are similar to South 
Korea in general. Please refer to online supplemental 
tables S1- 1–S1- 5 and figures S3–S6 for details.
We performed a sensitivity analysis of the TB burden 
in 2040 regarding model parameters in the same way as 
in South Korea (online supplemental figure S7). The 
results are almost identical in that the progression rate 
from the low- risk latent to infectious, the proportion of 
DS treatment success, diagnostic delay and transmission 
rate played significant roles in the DS- TB and MDR- TB 
infection dynamics.
DISCUSSION
New DS- TB and MDR- TB cases in Korea have steadily 
declined from 2011 to the present. According to the 2018 
Tuberculosis Annual Report,8 the number of new patients 
with pulmonary TB decreased from 30 100 new cases in 
2011 to 20 883 new cases in 2018. While the steady TB 
control strategy has reduced the TB incidence, based on 
the results of the simulation using a mathematical model, 
in the long term, the current decline is not expected to 
continue. By maintaining the current level of preventive 
control strategy until 2025, new TB cases are expected 
to decrease by only 14.5% from 2019 to 2040, contrasted 
with the 19.9% reduction between 2011 and 2019. The 
long- term incubation period of TB is believed to be 
responsible for this mitigation. The latent TB infection 
rate among Koreans is 33.2%, which is approximately 
17 million people as of 2016.14 Our model simulations 
predicted that the number of people in the low- risk 
latent compartment would decrease very slowly. This is 
because none of the major TB control strategies directly 
target low- risk latent groups.
Contact investigation and preventive therapy for the 
close contact group had a significant impact on the 
reduction of new TB cases from 2011 to 2019. However, 
the long- term impact of preventive therapy for close 
contacts is not expected to be as effective as currently, 
due to TB having a long incubation period and a consid-
erable population being latently infected in South Korea. 
Implementing the preventive therapy control from 2020 
to 2025, 1.5 times the level of control during the period 
from 2011 to 2019, the decrease in new TB cases from 
2019 to 2025 was only 8.5%, while the reduction from 
Table 5 Cumulative number of reported TB cases, annual new infection and death predictions with active case- finding in 
South Korea
2020 2025 2030 2035 2040
Cumulative DS report 31 909 170 422 298 130 418 910 533 296
Cumulative MDR report 696 3430 5810 8066 10 226
Yearly new infection 86 530 73 117 70 073 67 486 64 953
Death by TB 4308 3395 3174 3005 2847
DS, drug- susceptible ; MDR, multidrug- resistant; TB, tuberculosis.
Table 6 Cumulative number of reported TB cases, annual new infection and death predictions with improvement of 
treatment success rate for DS- TB in South Korea
2020 2025 2030 2035 2040
Cumulative DS report 29 059 165 060 292 373 413 612 529 213
Cumulative MDR report 582 2925 5014 7008 8934
Yearly new infection 94 356 86 737 83 625 80 986 78 394
Death by TB 4514 4015 3790 3612 3446
DS, drug- susceptible ; MDR, multidrug- resistant; TB, tuberculosis.
Table 7 Cumulative number of reported TB cases, yearly new infection and death predictions with improvement of treatment 
success rate for MDR- TB in South Korea
2020 2025 2030 2035 2040
Cumulative DS report 29 762 171 915 305 410 432 707 554 254
Cumulative MDR report 632 3563 6349 9054 11 692
Yearly new infection 96 735 91 194 88 040 85 365 82 737
Death by TB 4579 4233 4008 3827 3658
DS, drug- susceptible ; MDR, multidrug- resistant; TB, tuberculosis.
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2011 to 2019 was 19.9%. Thus, a comprehensive TB 
control strategy is required to achieve the TB elimination 
goal in South Korea.
The quick and accurate diagnosis of TB and drug resis-
tance was found to be more effective for RR/MDR- TB 
than for DS- TB. This is because, at the baseline, only 
9% of RR/MDR- TB cases are treated immediately 
without hospital delay; diagnosis of RR/MDR- TB can be 
improved more than for than DS- TB. This implies that 
Figure 5 Number of reported TB cases with active 
case- finding in South Korea. DS, drug- susceptible; MDR, 
multidrug- resistant; TB, tuberculosis.
Figure 6 Number of reported TB cases with improvement 
of treatment success rate for DS- TB in South Korea. DS, 
drug- susceptible; MDR, multidrug- resistant; TB, tuberculosis.
Figure 7 Number of reported TB cases with improvement 
of treatment success rate for RR/MDR- TB in South Korea. 
DS, drug- susceptible; MDR, multidrug- resistant; RR, 
rifampin- resistant; TB, tuberculosis.
Figure 8 Sensitivity analysis of TB burden in 2040 regarding 
model parameters in South Korea. DS, drug- susceptible; 
MDR, multidrug- resistant; TB, tuberculosis.
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the scale- up of rapid RR/MDR- TB diagnostic capacities 
such as rolling out of the Xpert MTB/RIF assay can help 
to reduce the number of cases of RR/MDR- TB in South 
Korea.
Worldwide, early case- finding and effective treatment 
are the principal strategies for controlling TB transmis-
sion and reduce incidence.15 16 The improvement in the 
treatment success rate and the active case- finding strategy 
were found to have the most immediate effect among the 
interventions in our study (figure 9). The higher treat-
ment success rate was substantially effective and mean-
ingful in terms of RR/MDR- TB control in particular. The 
estimated proportion of TB cases with RR/MDR was 9.2% 
among previously treated cases in South Korea, which 
increased to 25% among re- treatment cases after treat-
ment failure.4 17 If the treatment success rate for DS- TB 
increases, then the number of re- treatment patients 
decreases, which reduces the number of patients with 
RR/MDR- TB. The other policy is expected to decrease 
the number of low- risk latent groups in the long term by 
reducing the infectious period of TB, which significantly 
curbs new infections.
Estimated data on reported TB cases in North Korea 
show that incidence rates remained constant between 
2012 and 20194 18 and preventive treatment strategy may 
be implemented in children under 5 years in familial 
contact based on WHO recommendation19 in North 
Korea. It might take time to implement active contact 
investigation and preventive treatment for all age in 
North Korea. Therefore, in the North Korean base-
line scenario, preventive therapy control was assumed 
to remain constant from 2012 to 2040. Some parame-
ters used in the North Korean model were determined 
in consideration of the resource limited situation in 
health system, malnutrition and high smoking rate 
compared with South Korea. Under these assumptions, 
it is predicted that the number of new TB cases will not 
decrease significantly.
In North Korea, the active case- finding was found to be 
most effective followed by preventive treatment. In our 
predicted model, RR/MDR- TB cases consistently would 
be a huge burden in North Korea. In fact, the diagnostic 
and treatment capacities for RR/MDR- TB in North 
Korea are scarce. The Ministry of Public Health of North 
Korea first began diagnosing and treating MDR- TB in 
2008 with support from the Eugene Bell Foundation 
(EBF), a non- governmental organisation.20 However, 
the EBF programme did not cover all of North Korea. 
In 2010, the Global Fund to Fight AIDS, TB, and Malaria 
(GFATM) began a major project to strengthen TB control 
in North Korea,21 but a small portion of this international 
aid was allocated for the treatment of drug- resistant TB.22 
In addition, the tight UN sanctions due to the nuclear 
programme of North Korea have made it difficult to 
maintain the humanitarian assistance operations for the 
management of TB and MDR- TB in North Korea.23 In 
fact, GFATM closed its grant for North Korea in June 
2018 and reached new agreement in 2020.24 North Korea 
is one of the high burden country of both TB and RR/
MDR- TB.4 Unstable drug supply and delayed diagnosis 
of TB and drug resistance would further increase the 
development of drug resistance in North Korea. Even in 
our model, which assumed the stable supply of TB drugs 
and diagnostics, RR/MDR- TB in North Korea increased 
in 2040. Thus, to overcome the burden of RR/MDR- TB 
in North Korea, a sustainable and comprehensive TB 
control strategy that focuses on both DS- TB and RR/
MDR- TB is necessary.
Limitations
Despite the strengths, this study has several limitations. 
First, age was not considered in the model to describe 
TB infection dynamics. Progression rate from latent state 
to active infectious state in TB and death rate may differ 
according to age.25 Second, it is assumed that infectivity 
remains constant during patient delay. However, the infec-
tivity of TB can vary depending on the degree of disease 
progression and coughing and may not be constant 
during the patient delay period. Third, we hypothesised 
that decline of TB cases has been accelerated due to 
increased contact investigation and preventive treatment 
interventions to calibrate the model. However, the source 
actions of the current trend of decreasing number of new 
TB cases are unclear, since South Korea has carried out 
several interventions simultaneously to reduce the inci-
dence of TB. Some other factors, including patient delay, 
hospital delay and low- risk latent to infectious, may have 
contributed to the reduction in TB cases during this 
period. In addition, there was an expansion of universal 
health coverage for TB treatment as social protection and 
strengthening the occupational health programme for 
TB. However, due to the lack of evidence for the impact 
of these factors on TB incidence, they were considered 
constant. Fourth, external aspects of the disease, such as 
changes in disease- related perceptions, were not consid-
ered. Research on TB awareness showed that the rate of 
Figure 9 Reduction of cumulative TB cases from 2020- 
2040 under different intervention scenarios compared to the 
baseline in South Korea. Blue and red represent reductions 
in DS- TB and RR/MDR- TB cases, respectively. ACF, Active 
case- finding; DI, Diagnostic improvement; PT, Preventive 
treatment; TSR- DS, Treatment success rate for DS- TB; TSR- 
MDR, Treatment success rate for RR/MDR- TB.
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willingness to screen for TB improved from 53.2% in 2013 
to 62.7% in 2015.26 This suggests that apart from direct 
interventions, improved awareness can also decrease 
patient delay. Finally, the values of many parameters were 
assumed because of the lack of available information in 
North Korea.
CONCLUSION
The results show that intervention strategies in the order 
of improvement of treatment success rate for DS- TB, 
active case- finding, preventive therapy, reduced hospital 
delay and improvement of treatment success rate for 
RR/MDR- TB in South Korea are effective (figure 9). 
In particular, the treatment success rate increment for 
DS- TB has the most effect in reducing RR/MDR- TB. In 
North Korea, active case finding has the greatest impact 
on new TB incidence followed by the preventive therapy 
and treatment success rate for DS- TB (figure 8).
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